

## Triclabendazole / Abamectin Formulation

Version 2.8      Revision Date: 30.09.2023      SDS Number: 5341817-00011      Date of last issue: 04.04.2023  
Date of first issue: 05.12.2019

---

**SECTION 1. IDENTIFICATION**

Product name : Triclabendazole / Abamectin Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : Talcahuano 750, 6th floor, Ciudad Autonoma  
Buenos Aires, Argentina C1013AAP

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Liver, Blood)

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

**GHS label elements**

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H373 May cause damage to organs (Liver, Blood) through prolonged or repeated exposure if swallowed.  
H410 Very toxic to aquatic life with long lasting effects.

Precautionary Statements : **Prevention:**  
P260 Do not breathe mist or vapors.  
P273 Avoid release to the environment.

## Triclabendazole / Abamectin Formulation

Version 2.8      Revision Date: 30.09.2023      SDS Number: 5341817-00011      Date of last issue: 04.04.2023  
 Date of first issue: 05.12.2019

**Response:**

P314 Get medical advice/ attention if you feel unwell.  
 P391 Collect spillage.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Triclabendazole	68786-66-3	>= 10 -< 20
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	>= 0,0025 -< 0,025

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
 Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.  
 Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.  
 Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention if symptoms occur.  
 Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical

Unsuitable extinguishing media : None known.

## Triclabendazole / Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.8	30.09.2023	5341817-00011	Date of first issue: 05.12.2019

---

- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- 

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g., by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
- 

### SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe mist or vapors.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

## Triclabendazole / Abamectin Formulation

Version 2.8      Revision Date: 30.09.2023      SDS Number: 5341817-00011      Date of last issue: 04.04.2023  
 Date of first issue: 05.12.2019

- assessment  
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Triclabendazole	68786-66-3	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
Further information: DSEN				
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	TWA	15 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	150 µg/100 cm <sup>2</sup>	Internal

- Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

**Personal protective equipment**

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.  
 Additional body garments should be used based upon the

## Triclabendazole / Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.8	30.09.2023	5341817-00011	Date of first issue: 05.12.2019

---

task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance	:	suspension
Color	:	white
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	5,0 - 7,0
Melting point/freezing point	:	< 5 °C
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	1.050 - 1.080 g/cm <sup>3</sup> (20 °C)
Solubility(ies)	:	

## Triclabendazole / Abamectin Formulation

Version 2.8      Revision Date: 30.09.2023      SDS Number: 5341817-00011      Date of last issue: 04.04.2023  
Date of first issue: 05.12.2019

---

Water solubility : soluble

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

    Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute dermal toxicity : Acute toxicity estimate: > 5.000 mg/kg  
Method: Calculation method

**Components:****Triclabendazole:**

Acute oral toxicity : LD50 (Mouse): > 8.000 mg/kg  
LD50 (Rabbit): 206 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0,5 mg/l

---

**Triclabendazole / Abamectin Formulation**

Version 2.8      Revision Date: 30.09.2023      SDS Number: 5341817-00011      Date of last issue: 04.04.2023  
Date of first issue: 05.12.2019

---

Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rat): > 4.000 mg/kg

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Acute oral toxicity : LD50 (Rat): 24 mg/kg

LD50 (Mouse): 10 mg/kg

LDLo (Monkey): 24 mg/kg

Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0,023 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg

LD50 (Rabbit): 2.000 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Triclabendazole:**

Species : Rabbit  
Result : Mild skin irritation

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Triclabendazole:**

Species : Rabbit  
Result : No eye irritation

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rabbit  
Result : Mild eye irritation

**Triclabendazole / Abamectin Formulation**

Version 2.8      Revision Date: 30.09.2023      SDS Number: 5341817-00011      Date of last issue: 04.04.2023  
Date of first issue: 05.12.2019

---

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Triclabendazole:**

Result : Not a skin sensitizer.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Result : Not a skin sensitizer.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Triclabendazole:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster lung cells  
Result: negative  
  
Test Type: Alkaline elution assay  
Result: negative  
  
Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

**Carcinogenicity**

Not classified based on available information.



**Triclabendazole / Abamectin Formulation**

Version 2.8      Revision Date: 30.09.2023      SDS Number: 5341817-00011      Date of last issue: 04.04.2023  
Date of first issue: 05.12.2019

---

**Components:****Triclabendazole:**

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rat  
Application Route : Oral  
Exposure time : 105 weeks  
Result : negative

Species : Mouse  
Application Route : Oral  
Exposure time : 93 weeks  
Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Triclabendazole:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Application Route: Oral  
Fertility: NOAEL: 50 mg/kg body weight  
Result: No effects on fertility.

Test Type: Fertility/early embryonic development  
Application Route: Oral  
Fertility: NOAEL: 50 mg/kg body weight  
Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 5,5 mg/kg body weight

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 200 mg/kg body weight  
Result: Effects on fetal development.

Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral

## Triclabendazole / Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.8	30.09.2023	5341817-00011	Date of first issue: 05.12.2019

---

Developmental Toxicity: NOAEL: 50 mg/kg body weight

Test Type: Embryo-fetal development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 10 mg/kg body weight  
 Result: Effects on fetal development.  
 Remarks: Maternal toxicity observed.

Test Type: Embryo-fetal development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 3 mg/kg body weight  
 Remarks: Maternal toxicity observed.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Effects on fertility : Test Type: Fertility  
 Species: Rat, male  
 Application Route: Oral  
 Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Oral  
 Early Embryonic Development: NOAEL: 0,12 mg/kg body weight  
 Result: Fetotoxicity.

Effects on fetal development : Test Type: Embryo-fetal development  
 Species: Mouse  
 Application Route: Oral  
 General Toxicity Maternal: NOAEL: 0,05 mg/kg body weight  
 Developmental Toxicity: NOAEL: 0,2 mg/kg body weight  
 Result: Cleft palate  
 Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 2 mg/kg body weight  
 Result: Cleft palate, Teratogenic effects., Reduced embryonic survival  
 Remarks: Adverse developmental effects were observed

Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 1,6 mg/kg body weight  
 Result: Teratogenic effects.

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

## Triclabendazole / Abamectin Formulation

Version 2.8      Revision Date: 30.09.2023      SDS Number: 5341817-00011      Date of last issue: 04.04.2023  
Date of first issue: 05.12.2019

---

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

May cause damage to organs (Liver, Blood) through prolonged or repeated exposure if swallowed.

**Components:****Triclabendazole:**

Target Organs : Liver, Blood  
Assessment : May cause damage to organs through prolonged or repeated exposure.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Routes of exposure : Ingestion  
Target Organs : Central nervous system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Triclabendazole:**

Species : Rat  
NOAEL : 6,6 mg/kg  
LOAEL : 69 mg/kg  
Application Route : Oral  
Exposure time : 13 Weeks  
Target Organs : Blood

Species : Dog  
NOAEL : 3,4 mg/kg  
LOAEL : 37 mg/kg  
Application Route : Oral  
Exposure time : 13 Weeks  
Target Organs : Liver, Blood

Species : Mouse  
NOAEL : 29 mg/kg  
Application Route : Oral  
Exposure time : 24 Months  
Target Organs : Liver

Species : Rat  
NOAEL : 4 mg/kg  
Application Route : Oral  
Exposure time : 24 Months  
Remarks : No significant adverse effects were reported

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

## Triclabendazole / Abamectin Formulation

Version 2.8      Revision Date: 30.09.2023      SDS Number: 5341817-00011      Date of last issue: 04.04.2023  
 Date of first issue: 05.12.2019

Species : Rat  
 NOAEL : 1,5 mg/kg  
 Application Route : Oral  
 Exposure time : 24 Months  
 Target Organs : Central nervous system  
 Symptoms : Tremors, ataxia

Species : Mouse  
 NOAEL : 4,0 mg/kg  
 Application Route : Oral  
 Exposure time : 24 Months  
 Target Organs : Central nervous system  
 Symptoms : Tremors, ataxia

Species : Dog  
 NOAEL : 0,25 mg/kg  
 LOAEL : 0,5 mg/kg  
 Application Route : Oral  
 Exposure time : 53 Weeks  
 Target Organs : Central nervous system  
 Symptoms : Tremors, weight loss  
 Remarks : mortality observed

Species : Monkey  
 NOAEL : 1,0 mg/kg  
 Application Route : Oral  
 Exposure time : 14 Weeks  
 Target Organs : Central nervous system

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Triclabendazole:**

Ingestion : Symptoms: Abdominal pain, Sweating, Headache, Nausea, Vomiting, anorexia, Dizziness, Fatigue, Cough, Fever, pruritis

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Ingestion : Symptoms: May cause, Tremors, Diarrhea, central nervous system effects, Salivation, tearing

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3,2 µg/l  
 Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9,6 µg/l

## Triclabendazole / Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.8	30.09.2023	5341817-00011	Date of first issue: 05.12.2019

---

	Exposure time: 96 h
	LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l Exposure time: 96 h
	LC50 (Cyprinus carpio (Carp)): 42 µg/l Exposure time: 96 h
	LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Americamysis): 0,022 µg/l Exposure time: 96 h
	EC50 (Daphnia magna (Water flea)): 0,34 µg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h
M-Factor (Acute aquatic toxicity)	: 10.000
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 0,52 µg/l Exposure time: 32 d
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0,03 µg/l Exposure time: 21 d
	NOEC (Mysidopsis bahia (opossum shrimp)): 0,0035 µg/l Exposure time: 28 d
M-Factor (Chronic aquatic toxicity)	: 10.000
Toxicity to microorganisms	: EC50: > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition

**Persistence and degradability****Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Stability in water	: Hydrolysis: 50 %(< 12 h)
--------------------	----------------------------

**Bioaccumulative potential****Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Bioaccumulation	: Bioconcentration factor (BCF): 52
-----------------	-------------------------------------

Partition coefficient: n-octanol/water	: log Pow: 4
--	--------------

## Triclabendazole / Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.8	30.09.2023	5341817-00011	Date of first issue: 05.12.2019

**Mobility in soil****Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Distribution among environmental compartments : log K<sub>oc</sub>: > 3,6

**Other adverse effects**

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO))

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO))

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 964

Packing instruction (passenger aircraft) : 964

Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO))

Class : 9

**Triclabendazole / Abamectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.8	30.09.2023	5341817-00011	Date of first issue: 05.12.2019

---

Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**SECTION 16. OTHER INFORMATION**Revision Date : 30.09.2023  
Date format : dd.mm.yyyy**Further information**Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>**Full text of other abbreviations**

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-

## Triclabendazole / Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.8	30.09.2023	5341817-00011	Date of first issue: 05.12.2019

---

tem; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8